These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 16780548

  • 1. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.
    Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
    Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V.
    Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
    [Abstract] [Full Text] [Related]

  • 5. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 6. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 15; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

  • 7. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 15; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 8. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 15; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 9. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Oct 15; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 10. Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience.
    Hellemans R, Beutels P, Ieven M, Verpooten GA, Bosmans JL.
    Transpl Infect Dis; 2013 Feb 15; 15(1):70-8. PubMed ID: 23173691
    [Abstract] [Full Text] [Related]

  • 11. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.
    Ann Intern Med; 2015 Jan 06; 162(1):1-10. PubMed ID: 25560711
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV.
    Transplantation; 2005 Jan 15; 79(1):85-90. PubMed ID: 15714174
    [Abstract] [Full Text] [Related]

  • 13. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 14. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.
    BMC Infect Dis; 2010 Jan 06; 10():2. PubMed ID: 20053269
    [Abstract] [Full Text] [Related]

  • 15. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2008 Feb 06; 14(2):240-4. PubMed ID: 18236404
    [Abstract] [Full Text] [Related]

  • 16. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
    Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D.
    Am J Transplant; 2005 Jun 06; 5(6):1462-8. PubMed ID: 15888055
    [Abstract] [Full Text] [Related]

  • 17. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 18. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A, RESITRA.
    Clin Infect Dis; 2008 Jan 01; 46(1):20-7. PubMed ID: 18171208
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 01; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 20. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.
    Helanterä I, Lautenschlager I, Koskinen P.
    Nephrol Dial Transplant; 2009 Jan 01; 24(1):316-20. PubMed ID: 18842670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.